SARcode's Dry Eye Drug Hits Endpoint in First Phase III Trial
By Jennifer Boggs
Monday, October 22, 2012
SARcode Bioscience Inc. cleared the first hurdle in its Phase III program testing dry eye candidate lifitegrast, with the drug nailing its primary endpoint in the first pivotal trial, demonstrating biologic activity against ocular surface damage.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.